Eli Lilly and Company operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Eli Lilly and Company with three other
companies in this sector in the United States:
sales of $20.41 billion
of which 34%
of which 100%
was Pharmaceutical Products), and
Teva Pharmaceutical Industries Limited
of which 49%
was Generic Madicines).
Eli Lilly and Company reported sales of $19.96 billion
December of 2015.
a very small
increase of 1.7%
versus 2014, when the company's sales were $19.62 billion.
Despite this increase, sales are still
below the level achieved in 2013, when Eli Lilly and Company
reported sales of $23.11 billion.
Sales of Animal Health saw an increase
that was more than double the company's growth rate: sales were up
35.6% in 2015, from
$2.35 billion to $3.18 billion.
Eli Lilly and Company also saw significant increases in sales in
Oncology (up 3.4% to $3.51 billion)
Not all segments of Eli Lilly and Company experienced an increase in sales in 2015:
sales of Other Pharmaceutical fell 20.7% to $227.70 million.
(However, this segment's sales were only a very small portion of the company's overall sales).
Eli Lilly and Company also experienced decreases in sales in
Neurosciences (down 18.4% to $2.94 billion)